Avanos Medical (NYSE:AVNS - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.40 per share and revenue of $177.23 million for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.
Avanos Medical Trading Up 0.0 %
Shares of NYSE AVNS traded up $0.01 during midday trading on Friday, reaching $15.49. 350,491 shares of the stock were exchanged, compared to its average volume of 432,212. The stock has a 50 day moving average price of $16.22 and a 200-day moving average price of $19.87. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $711.78 million, a P/E ratio of 45.55 and a beta of 0.98. Avanos Medical has a 52-week low of $14.98 and a 52-week high of $25.36.
Wall Street Analyst Weigh In
Separately, StockNews.com downgraded Avanos Medical from a "strong-buy" rating to a "buy" rating in a report on Sunday, November 3rd.
View Our Latest Research Report on AVNS
Avanos Medical Company Profile
(
Get Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Read More
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
